Loss of activating transcription factor 3 prevents KRAS-mediated pancreatic cancer

被引:0
|
作者
Nawab Azizi
Jelena Toma
Mickenzie Martin
Muhammad Faran Khalid
Fatemeh Mousavi
Phyo Wei Win
Maria Teresa Borrello
Nina Steele
Jiaqi Shi
Marina Pasca di Magliano
Christopher L. Pin
机构
[1] Children’s Health Research Institute,Department of Physiology and Pharmacology
[2] University of Western Ontario,Department of Oncology
[3] University of Western Ontario,Department of Biology
[4] University of Western Ontario,Department of Paediatrics
[5] University of Western Ontario,Centre for Cancer Research Marseille, INSERM U1068, CNRS UMR 7258
[6] Aix-Marseille Université and Institut Paoli-Calmettes,Department of Pathology
[7] University of Michigan,Department of Surgery
[8] University of Michigan,undefined
来源
Oncogene | 2021年 / 40卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
The unfolded protein response (UPR) is activated in pancreatic pathologies and suggested as a target for therapeutic intervention. In this study, we examined activating transcription factor 3 (ATF3), a mediator of the UPR that promotes acinar-to-ductal metaplasia (ADM) in response to pancreatic injury. Since ADM is an initial step in the progression to pancreatic ductal adenocarcinoma (PDAC), we hypothesized that ATF3 is required for initiation and progression of PDAC. We generated mice carrying a germline mutation of Atf3 (Atf3−/−) combined with acinar-specific induction of oncogenic KRAS (Ptf1acreERT/+KrasG12D/+). Atf3−/− mice with (termed APK) and without KRASG12D were exposed to cerulein-induced pancreatitis. In response to recurrent pancreatitis, Atf3−/− mice showed decreased ADM and enhanced regeneration based on morphological and biochemical analysis. Similarly, an absence of ATF3 reduced spontaneous pancreatic intraepithelial neoplasia (PanIN) formation and PDAC in Ptf1acreERT/+KrasG12D/+ mice. In response to injury, KRASG12D bypassed the requirement for ATF3 with a dramatic loss in acinar tissue and PanIN formation observed regardless of ATF3 status. Compared to Ptf1acreERT/+KrasG12D/+ mice, APK mice exhibited a significant decrease in pancreatic and total body weight, did not progress through to PDAC, and showed altered pancreatic fibrosis and immune cell infiltration. These findings suggest a complex, multifaceted role for ATF3 in pancreatic cancer pathology.
引用
收藏
页码:3118 / 3135
页数:17
相关论文
共 50 条
  • [21] Pancreatic stellate cells activated by mutant KRAS-mediated PAI-1 upregulation foster pancreatic cancer progression via IL-8
    Wang, Hao-Chen
    Lin, Yung-Lun
    Hsu, Ching-Cheng
    Chao, Ying-Jui
    Hou, Ya-Chin
    Chiu, Tai-Jan
    Huang, Po-Hsien
    Tang, Ming-Jer
    Chen, Li-Tzong
    Shan, Yan-Shen
    THERANOSTICS, 2019, 9 (24): : 7168 - 7183
  • [22] Role Of Nicotine And Alpha 7 Nicotinic Acetylcholine Receptors In Kras-Mediated Lung Cancer
    Torres-Gonzalez, E.
    Ritzenthaler, J. D.
    Roman, J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2014, 189
  • [23] KRAS-mediated therapeutic resistance abrogates immunogenic cell death in colorectal cancer cells
    Wang, Yi-Jun
    Chen, Dongshi
    Tong, Jingshan
    Yu, Jian
    Bardelli, Alberto
    Zhang, Lin
    CANCER RESEARCH, 2017, 77
  • [24] Loss of runt-related transcription factor 3 induces gemcitabine resistance in pancreatic cancer
    Horiguchi, Shigeru
    Shiraha, Hidenori
    Nagahara, Teruya
    Kataoka, Jyunnro
    Iwamuro, Masaya
    Matsubara, Minoru
    Nishina, Shinichi
    Kato, Hironari
    Takaki, Akinobu
    Nouso, Kazuhiro
    Tanaka, Takehiro
    Ichimura, Koichi
    Yagi, Takahito
    Yamamoto, Kazuhide
    MOLECULAR ONCOLOGY, 2013, 7 (04) : 840 - 849
  • [25] Activating transcription factor 3 promotes colon cancer metastasis
    Wu, Zhi-Yong
    Wei, Zheng-mao
    Sun, Sheng-Jie
    Yuan, Jing
    Jiao, Shun-Chang
    TUMOR BIOLOGY, 2014, 35 (08) : 8329 - 8334
  • [26] Mutant KRas-mediated AKT2 activation supports lung cancer growth by activating complex II-driven mitochondrial metabolism
    Park, Kwan-Hee
    Lee, Ho-Young
    CANCER RESEARCH, 2017, 77
  • [27] ERK3/MAPK6 is required for KRAS-mediated NSCLC tumorigenesis
    Katarzyna Bogucka
    Federico Marini
    Sebastian Rosigkeit
    Janine Schloeder
    Helmut Jonuleit
    Kerstin David
    Margarita Schlackow
    Krishnaraj Rajalingam
    Cancer Gene Therapy, 2021, 28 : 359 - 374
  • [28] Deficient Rnf43 potentiates hyperactive Kras-mediated pancreatic preneoplasia initiation and malignant transformation
    Zhou, Xian
    Sun, Zhichao
    Zhang, Mengdi
    Qu, Xiaoyu
    Yang, Shuhui
    Wang, Lianmei
    Jing, Yanling
    Li, Li
    Deng, Weiwei
    Liu, Fangming
    Di, Jin
    Chen, Jie
    Wu, Jian
    Zhang, Hongbing
    ANIMAL MODELS AND EXPERIMENTAL MEDICINE, 2022, 5 (01) : 61 - 71
  • [29] ERK3/MAPK6 is required for KRAS-mediated NSCLC tumorigenesis
    Bogucka, Katarzyna
    Marini, Federico
    Rosigkeit, Sebastian
    Schloeder, Janine
    Jonuleit, Helmut
    David, Kerstin
    Schlackow, Margarita
    Rajalingam, Krishnaraj
    CANCER GENE THERAPY, 2021, 28 (05) : 359 - 374
  • [30] KRAS-mediated upregulation of CIP2A promotes suppression of PP2A-B56α to initiate pancreatic cancer development
    Tinsley, Samantha L.
    Chianis, Ella Rose D.
    Shelley, Rebecca A.
    Mall, Gaganpreet K.
    Dhiman, Alisha
    Baral, Garima
    Kothandaraman, Harish
    Thoma, Mary C.
    English, Isabel A.
    Daniel, Colin J.
    Acosta, Luis Carlos Sanjuan
    Solorio, Luis
    Lanman, Nadia Atallah
    di Magliano, Marina Pasca
    Narla, Goutham
    Dykhuizen, Emily C.
    Sears, Rosalie C.
    Allen-Petersen, Brittany L.
    ONCOGENE, 2024, 43 (50) : 3673 - 3687